Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Opinion|Videos|January 31, 2025 (Updated: January 31, 2025)
Overview of Process of CAR-T Therapy
This segment examines the decision-making process between CAR-T therapy and other innovative treatments, exploring scenarios where alternative therapies may be more appropriate.
Advertisement
Video content above is prompted by the following:
- How do you weigh the choice between CAR-T therapy and other innovative agents?
- Under what circumstances might you consider alternative treatments over CAR-T?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.